Zykadia Better than Chemo as Second-line Treatment of Specific Lung Cancer, Trial Finds
News
Patients with non-small cell lung cancer (NSCLC) who have an ALK gene rearrangement and who were previously treated with the ALK inhibitor Xalkori (crizotinib) may strongly benefit from treatment with another ... Read more